ft 12 oct 93 cheap drug attract giant growth gener driven expiri patent hoechst dollar 550m pound 364m acquisit last week major stake copley pharmaceut us gener drug manufactur surpris drug industri price deal one largest dollar 5 5bn us gener drug sector manufactur cheap medicin whose patent expir dollar 550m price tag valu copley 87 time net profit dollar 12 3m last year high multipl standard howev mr jurgen dormann hoechst financ director said price appropri view copley profit net return sale least 24 per cent hoechst strategi enter us gener non patent prescript medicin busi howev predict latest seri move pharmaceut group enter fast grow sector past two year 1980 trend compani leav low margin high volum gener industri revers gener market grow rapidli increasingli import drug lose patent cost consciou healthcar provid becom interest cheap gener medicin research base pharmaceut group market gener version drug extend earn stream earlier month marion merrel dow acquir rugbi darbi gener oper largest gener busi us sale dollar 280m drug group recent join gener industri includ merck world largest drug group bristol myer third largest compani tempt rapid expans us gener sector hoechst expect grow 14 per cent year rest decad kline amp co new york base industri analyst estim sector could doubl size dollar 10bn year 1992 1996 compar favour entir us prescript drug market grew 3 per cent first six month year accord im intern market research group slowdown expect worsen short term gener market driven import patent expir last year seven drug combin annual sale dollar 2 5bn came patent us year patent 11 medicin yearli sale dollar 3bn expir signific includ syntex anti inflammatori naprosyn next month seldan marion merrel dow anti histamin april smithklin beecham tagamet may biggest bristol myer squibb heart drug capoten sale dollar 1 6bn becom vulner gener competit 1995 pharmaceut group want manufactur gener version extend product earn marion merrel dow produc gener version heart drug cardizem warner lambert make gener cholesterol lower product lopid explos gener sale also encourag chang market bulk purchas health increasingli prescrib cheap gener rather prici patent medicin 1991 40 per cent prescript us gener figur expect reach 66 per cent 1995 accord kline amp co hoechst believ clinton healthcar reform willboost demand foremost problem face drug group want exploit us gener market enter option includ acquisit set scratch partnership group set compani includ rhone poulenc rorer franco american group eli lilli bristol myer squibb us uk zeneca merck plan introduc patent version 10 product west point pharma subsidiari other form partnership upjohn exampl form allianc wyeth ayerst laboratori subsidiari american home product market gener form upjohn hormon replac therapi upjohn also sign agreement geneva pharmaceut subsidiari ciba switzerland market xanax anti anxieti treatment halcion sleep pill whose patent expir last month compani pfizer smithklin beecham quit sector may review strategi compani ciba never left research base pharmaceut group must quick market product gener compani prove increasingli aggress abil market drug day patent expiri gener version becom avail price fall price gener zeneca best sell product tenormin fell 13 per cent first day patent expiri 25 per cent within two month 80 per cent six competitor given sector rapid growth rush gener look set continu share small group soar follow hoechst announc myland stock rose dollar 1 5 8 close dollar 30 1 2 pharmaceut resourc dollar 1 1 8 dollar 14 1 8 investor clearli believ potenti acquisit target pharmaceut giant want follow hoechst exampl eli lilli cut worker page 6 major drug come patent expiri drug manfactur market date dollarsm jan 1993 lopid warner lambert 420 feb ansaid upjohn 205 oct xanax upjohn 650 nov vepesid bristol myer squibb 275 dec lopressor ciba 275 naprosyn syntex 1 000 jan 1994 micronas upjohn 395 apr seldan marion merrel dow 850 may tagamet smithklin beecham 930 dec cardizem cd marion merrel dow 600 may 1995 dilacor xr rhone poulenc rorer 250 aug capoten bristol myer squibb 1 655 sep sandimmun sandoz 250 dec zantac form 1 glaxo 2 500 sourc hk amp compani